Investors and Media

Investing in the Future of Precision Neuropsychiatric Care

At Neurosterix, our mission is to transform care for people living with serious neuropsychiatric conditions by advancing a new class of precision medicines.  We are pioneering allosteric modulators – small molecules designed to fine-tune brain signaling with unmatched selectivity and safety.

Our lead program, NTX-253 (M4 PAM), has completed Phase 1 clinical studies, supported by a pipeline of first- and best-in-class programs that target key brain receptor systems. Backed by leading life sciences investors, we are approaching critical milestones that we believe can reshape the treatment landscape for psychosis, mood, and anxiety disorders.

Neurosterix at a Glance

Strong Foundation

$170M Raised to date by leading life science investors.

Pipeline Leadership: NTX-253 (M4 PAM) has completed Phase 1 single- and multiple-ascending-dose clinical studies of NTX-253; advancing into Phase 2 for schizophrenia. NTX-819 (mGlu7 NAM) progressing through preclinical development for mood and anxiety disorders

Differentiated Discovery Engine

200+ functional CNS assays, an 80,000+ compound library, and proprietary expertise in receptor pharmacology

Intellectual Property Strength

100+ patents and 30+ peer-reviewed publications

Experienced Team

Leadership with a proven track record advancing CNS therapies from discovery through approval and launch

Explore Our Science

Our Investors

  • Perceptive Advisors
  • Acorn Bioventures
  • RTW Investments
  • Janus Henderson Investors
  • GV
  • Ikarian Capital
  • Affinity Asset Advisors
  • Dellora Investments

Press Releases

Contact Us

Awards and Recognition

Neurosterix — Prix Galien USA Best Startup Nominee 2026

Prix Galien USA 2026 — Best Startup Nominee